<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328571</url>
  </required_header>
  <id_info>
    <org_study_id>1907NRC</org_study_id>
    <nct_id>NCT04328571</nct_id>
  </id_info>
  <brief_title>Effects of Enzymatic Digestion and Probiotic on Oleuropein Bioavailability</brief_title>
  <official_title>Effects of Enzymatic Digestion and Probiotic on Oleuropein Bioavailability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-arms randomized-controlled, parallel group, single center, double-blind study
      investigating the bioavailability of olive oil extract (OLE) in two different OLE
      formulations (enzymatically treated and co-administered with a probiotic) compared to
      original OLE formulation in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male or female healthy adults between 25 and 65 years of age will be randomized into one of
      the 3 following groups to receive:

        1. Capsule of OLE + 1 stick of maltodextrin

        2. Capsule of OLE enzymatically treated + 1 stick of maltodextrin

        3. Capsule OLE + 1 stick of probiotic

      52 subjects will be randomized to achieve 15 subjects per group to complete the trial.

      The study will involve 3 phases:

        1. PK1 (all subjects will receive one capsule of OLE in the morning and blood samples will
           be collected at different timepoints for 24h) followed by a washout period of 1 day

        2. 3 weeks intervention (subjects will receive the product thy have benn assigned to)
           followed by a wash-out period of 3 days

        3. PK2 period (subjects will receive one capsule the product thy have benn assigned to
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3-arms randomized-controlled, parallel group, single center, double-blinded study investigating 3 different formulations of the investigational product</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Single coding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24h of individual blood oleuropein metabolites during PK2 period</measure>
    <time_frame>24 hours</time_frame>
    <description>AUC0-24h (concentration/time curve) of individual blood oleuropein metabolites during PK2 period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax during PK2 period</measure>
    <time_frame>24 hours</time_frame>
    <description>Cmax of total and individual oleuropein metabolites during PK2 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax during PK2 period</measure>
    <time_frame>24 hours</time_frame>
    <description>Tmax of total and individual oleuropein metabolites during PK2 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 during PK2 period</measure>
    <time_frame>24 hours</time_frame>
    <description>T1/2 of total and individual oleuropein metabolites during PK2 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of total and individual oleuropein metabolites in urine at PK2</measure>
    <time_frame>24 hours</time_frame>
    <description>Levels of total and individual oleuropein metabolites excreted in the urine collected over 24 hours during PK2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h during PK1</measure>
    <time_frame>24 hours</time_frame>
    <description>AUC0-24h (concentration/time curve) of individual blood oleuropein metabolites during PK1 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax during PK1</measure>
    <time_frame>24 hours</time_frame>
    <description>Cmax of total and individual blood oleuropein metabolites during PK1 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax during PK1</measure>
    <time_frame>24 hours</time_frame>
    <description>Tmax of total and individual blood oleuropein metabolites during PK1 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 during PK1</measure>
    <time_frame>24 hours</time_frame>
    <description>T1/2 of total and individual blood oleuropein metabolites during PK1 period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of total and individual oleuropein metabolites in urine at PK1</measure>
    <time_frame>24 hours</time_frame>
    <description>Levels of total and individual oleuropein metabolites excreted in the urine collected over 24 hours during PK1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota bacterial population diversity</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to end of the 3-week intervention period of gut microbiota bacterial population diversity (16SrDNA sequencing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of faecal oleuropein metabolites</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to end of the 3-week intervention period of faecal oleuropein metabolites</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of gut microbiota faecal short chain fatty acids</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to end of the 3-week intervention period of gut microbiota faecal short chain fatty acids (acetate, propionate, butyrate) &amp; lactate</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of gut microbiota faecal branched chain fatty acids</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to end of the 3-week intervention period of gut microbiota faecal branched chain fatty acids (isobutyrate, isovalerate &amp; isocaproate)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of gut microbiota faecal ammonium production</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to end of the 3-week intervention period of gut microbiota faecal ammonium production</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of total cholesterol</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of total cholesterol levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of LDL</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of LDL levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of HDL</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of HDL levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of ALAT</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of ALAT levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of ASAT</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of ASAT levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of creatinine</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of creatinine levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of glucose</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of glucose levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of triglycerides</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of triglycerides levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of bone biomarkers</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of bone biomarkers (P1NP, CTX)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood levels of Oxidized LDL</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change from baseline to the end of the 3-week intervention period of Oxidized LDL</description>
  </other_outcome>
  <other_outcome>
    <measure>Levels of biomarkers of oxidative stress</measure>
    <time_frame>3 weeks</time_frame>
    <description>8-NO2GU, 8-OH-GU, 8-OH GUO, 8-OH-DGUO, 8 NO2 GUO, cGMP, 8-NO2-cGMP, Prostanoids, Oxylipins, Isoprostanes, Phytoprostanes and Phytofuranes</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>OLE enzymatically treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLE + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OLE enzymatically treated</intervention_name>
    <description>OLE (Olive leaf extract ) enzymatically treated + maltodextrin</description>
    <arm_group_label>OLE enzymatically treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OLE + probiotic</intervention_name>
    <description>OLE (Olive leaf extract) co-administered with probiotic</description>
    <arm_group_label>OLE + probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OLE</intervention_name>
    <description>OLE (Olive leaf extract) + maltodextrin</description>
    <arm_group_label>OLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to sign written informed consent prior to trial entry

          2. Male or female healthy adults between 25 and 65 years of age

          3. Body Mass Index (BMI) within the range 18.5 - 29.9 (both inclusive)

          4. In good health as determined by medical judgment and medical history

        Exclusion Criteria:

          1. Any food allergy/intolerance

          2. Subjects not willing and/or not able to comply with scheduled visits and the
             requirements of the study protocol

          3. Taking or anticipated initiation of any lipid-modifying or blood-clotting medication
             e.g. statins, cholesterol lowering

          4. Smokers

          5. Alcohol intake higher than 2 servings per day (one serving is 0.4 dL of strong
             alcohol, 1 dL of wine, or 3 dL of beer) or drug abuse

          6. Receiving or having received antibiotics in the past 4 weeks prior to the day of
             inclusion

          7. Overly imbalanced or restrictive diet (e.g. hyperproteic, vegan, ketogenic, etc.)

          8. Hormonal treatment for women linked to menopause (contraceptive treatment accepted)

          9. Pregnancy or breastfeeding

         10. Supplements or foods containing probiotics (yogurts allowed)

         11. Currently participating or having participated in another clinical trial within 4
             weeks prior to trial start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco A. Tomás-Barberán, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEBAS-CSIC, Murcia, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecilia L. Fumero</last_name>
    <phone>+41 (0)21 785 8328</phone>
    <email>cecilia.fumero@rdls.nestle.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Noëlle Horcajada</last_name>
    <phone>+41 (0)21 785 8130</phone>
    <email>MarieNoelle.Horcajada@rdls.nestle.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidad Católica San Antonio</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco A. Tomás-Barberán, Prof.</last_name>
      <phone>+34-636256526</phone>
      <email>fatomas@cebas.csic.es</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Zafrilla, Dr.</last_name>
      <phone>+34-685607716</phone>
      <email>mpzafrilla@ucam.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

